NCT00565162View on ClinicalTrials.gov

Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

PHASE4CompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

June 30, 2005

Conditions

Diabetes Mellitus

Interventions

DRUG

Insulin Glargine

Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.

Trial Locations (4)

Unknown

Sanofi-Aventis, Helsinki

Sanofi-Aventis, Amsterdam

Sanofi-Aventis, Stockholm

Sanofi-Aventis, Leicester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT00565162 - Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus | Biotech Hunter | Biotech Hunter